Resveratrol vs NMN
The two halves of the stack David Sinclair has described taking: a putative sirtuin activator and an NAD+ precursor. Both have human trials, neither has a lifespan or hard-outcome result, and the combination itself has never been tested in a trial.
Resveratrol (trans-3,5,4'-trihydroxystilbene)
The polyphenol behind the sirtuin era of longevity research and one of the most heavily trialled supplements in this database: over 150 completed registered studies, results that conflict by population and dose rather than pointing one way, and no trial of lifespan or any hard clinical outcome in people.
Nicotinamide Mononucleotide
A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a contested regulatory status in the US.
| Attribute | Resveratrol | NMN |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Dietary supplement; not an approved drug. Labels may carry structure/function claims with the DSHEA disclaimer, but not disease treatment or prevention claims | Not an approved drug; US supplement status contested |
| Half-life | About 9 hours for resveratrol plus its sulfate and glucuronide conjugates after an oral dose; free parent compound is cleared far faster | Short |
| Molecular weight | 228.24 Da | 334.2 Da |
| Mechanism | Proposed as an allosteric activator of the NAD+-dependent deacetylase SIRT1, with downstream AMPK and PGC-1alpha signalling that mimics parts of calorie restriction. That direct-activation claim is disputed: groups at Amgen (2009) and Pfizer (2010) showed the measured activation depends on a fluorophore-tagged assay peptide and disappears with native substrates, while Sirtris and Sinclair's group argue in Science (2013) that activation is real but requires substrates carrying specific hydrophobic motifs and a single SIRT1 residue, Glu230. Independently of sirtuins, resveratrol has documented antioxidant activity, endothelial nitric oxide and flow-mediated dilation effects, and inhibition of CYP3A4, CYP2D6 and CYP2C9 at gram doses. | Converts to NAD+ through the salvage pathway, aiming to restore NAD+ levels that decline with age. |
| Legal status (US) | Sold as a dietary supplement; not an approved drug | Not approved; FDA excluded it from the supplement definition (2022) |
Frequently asked questions
What is the difference between Resveratrol and NMN?
Resveratrol: The polyphenol behind the sirtuin era of longevity research and one of the most heavily trialled supplements in this database: over 150 completed registered studies, results that conflict by population and dose rather than pointing one way, and no trial of lifespan or any hard clinical outcome in people. NMN: A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a contested regulatory status in the US.
Which has stronger research evidence, Resveratrol or NMN?
Resveratrol is rated Moderate and NMN is rated Preliminary for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Resveratrol and NMN FDA-approved?
Resveratrol: Dietary supplement; not an approved drug. Labels may carry structure/function claims with the DSHEA disclaimer, but not disease treatment or prevention claims. NMN: Not an approved drug; US supplement status contested.
Related posts
Blog articles that cover Resveratrol or NMN, newest first.
- Longevity · Sep 8, 2026 · 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Metabolic · Sep 8, 2026 · 7 minSLU-PP-332 and 5-Amino-1MQ: Two 'Peptides' That Are Not Peptides, and What the Mouse Data Actually Show
- Longevity · Sep 8, 2026 · 8 minNMN vs NR vs NAD+: The 2026 Head-to-Head Human Trials, and Who Funded the Comparisons
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.